Division of Diabetes Treatment and Prevention - Leading the effort to treat and prevent diabetes in American Indians and Alaska Natives |
|||||||||||||||||||||||||||||
|
Assessing CVD RiskRecommendations for Assessing CVD Risk
In diabetes patients without known CVD, it is important to calculate each patient’s CVD risk to determine appropriate risk reduction treatment goals and strategies. The Framingham Heart Study Risk Score Profile for 10-year risk of coronary heart disease is used most often for this purpose. Another option for calculating coronary heart disease risk in AI/AN patients is the Strong Heart Study risk calculator. Based on data collected among adults in thirteen American Indian Tribes in Arizona, North Dakota, South Dakota, and Oklahoma over the study’s 10-year period, the Strong Heart Study risk calculator is an appropriate tool to help determine treatment goals to reduce CVD risk in AI (and AN) patients. Back to TopBlood Pressure (BP) ManagementRecommendations for Blood Pressure
BP control reduces the risk for diabetic microvascular and macrovascular complications, and is essential in diabetes care. The 2011 IHS Diabetes Care and Outcomes Audit shows that, on average, AI/AN patients with diabetes are achieving excellent BP control, with a mean of 131/75 mmHg. Use of ACE inhibitors or ARB blockers has benefits not only for controlling BP but also for reducing albuminuria, a CVD risk marker. BP treatment requires diligent efforts to achieve targets. For those patients who can achieve a BP of < 130/80 mmHg without adverse symptoms, this target may be selected. For other patients, a target of < 140/90 mmHg (or higher if symptoms and comorbidities dictate) should be selected. Ensuring that patients with diabetes achieve and maintain individualized BP targets over the long term will improve outcomes for AI/AN patients. Back to TopLipids ManagementRecommendations for Lipids
→ Note: Lipid-lowering medications, especially used in combination, may adversely affect the liver. Consider baseline and interval laboratory assessment of liver enzymes. → Note: Statins are highly unsafe in pregnancy and are classified as Category X. Consider pregnancy risk when prescribing statins for reproductive age women. Lipid control in patients with diabetes is essential for reducing risk for macrovascular complications. The IHS Diabetes Care and Outcomes Audit data show that lipid control has been improving steadily among AI/AN patients with diabetes. LDL cholesterol levels have declined over the past decade, reaching an average level below 100 mg/dL. Patients with type 2 diabetes have an increased prevalence of lipid abnormalities, including high triglycerides and low HDL cholesterol levels. This pattern is a marker for small atherogenic LDL cholesterol particles that increase CVD risk, even when LDL cholesterol levels are not elevated. Recent research has shown that non-HDL cholesterol (total cholesterol minus HDL cholesterol) may be an even stronger measure of atherogenic load than LDL cholesterol alone. Therefore, it is reasonable to consider non-HDL cholesterol as a secondary lipid management target (< 130 mg/dL if no CVD, < 100 mg/dL if CVD). The most effective pharmacologic treatment to reduce risk for CVD events is statin therapy. Statins reduce CVD risk beyond LDL cholesterol reduction alone. While other classes of medications (e.g., fibrates, niacin, ezetimibe, and bile acid sequestrants) lower lipid values, research has not demonstrated that they reduce CVD risk. If the LDL cholesterol target is not achieved on a statin alone, combination therapy may be considered, however this has not been evaluated in studies for either CVD outcomes or safety. For patients who cannot tolerate one statin, it is reasonable to try using a different statin. If no statin is tolerated, a non-statin medication to lower LDL cholesterol may be considered, however, research has not demonstrated efficacy in reducing CVD risk in people with diabetes. Lifestyle therapy, including MNT addressing fat and cholesterol intake, increased physical activity, weight loss, and smoking cessation, is indicated for any patient with type 2 diabetes, even those with “normal” lipid levels. Goals for Lipid Control in Patients with Type 2 Diabetes
Peripheral Arterial Disease (PAD)Recommendations for Peripheral Arterial Disease
PAD is atherosclerosis of arteries to the head, organs, and limbs. PAD manifests most commonly in patients with diabetes as symptoms of leg claudication. If left untreated, PAD can progress to critical leg ischemia that can threaten limb viability. Moreover, PAD is a marker of systemic atherosclerosis, indicating patients are at increased risk for myocardial infarction (MI), stroke, and death. Risk factors associated with PAD include older age, cigarette smoking, diabetes, hypercholesterolemia, hypertension, and possibly genetic factors. Back to TopResourcesTools for Clinicians and EducatorsKey Tools and Resources Antiplatelet Therapy Aspirin for Primary Prevention of Cardiovascular Events in People with Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation [PDF]. 2010. Assessing CVD Risk IHS Division of Diabetes Treatment and Prevention.
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. [PDF] Circulation. 2010;122:e584-636. AHA/ADA Scientific Statement. Primary Prevention of Cardiovascular Diseases in People with Diabetes Mellitus: A Scientific Statement from the American Heart Association and the American Diabetes Association. [PDF] Circulation. 2007;115:114-26. Blood Pressure (BP) Management IHS Division of Diabetes Treatment and Prevention. National High Blood Pressure Education Program. National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 04-5230. 2004. Lipids Management IHS Division of Diabetes Treatment and Prevention. National Heart, Lung, and Blood Institute. National Institutes of Health.
Peripheral Arterial Disease 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease (Updating the 2005 Guideline). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2020-45, doi:10.1016/j.jacc.2011.08.023 (Published online 29 Sep 2011). PAD Coalition. Web-based resources for health professionals include Webcasts on PAD topics, online CME, and conference proceedings. Additional Resources National Heart, Lung, and Blood Institute and Indian Health Service. Honoring the Gift of Heart Health: A Heart Health Educator’s Manual for American Indians. [PDF] NIH Publication No. 06-5218. 2006. 303 p.
National Heart, Lung, and Blood Institute and Indian Health Service. Honoring the Gift of Heart Health: A Heart Health Educator’s Manual for Alaska Natives. [PDF] NIH Publication No. 06-5219. 2006. 309 p.
Patient Education MaterialsCardiovascular Care National Diabetes Education Program. Take Care of Your Heart. Manage Your Diabetes. [PDF] 2005.
National Heart, Lung, and Blood Institute. Dietary Approaches to Stop Hypertension (DASH) Eating Plan. [PDF] NIH Publication No. 06-4082. 2006. 58 p.
National Heart, Lung, and Blood Institute. Your Guide to Lowering Cholesterol with Therapeutic Lifestyle Changes (TLC). [PDF] NIH Publication No. 06–5235. 2005. 82 p.
National Institute of Diabetes and Digestive and Kidney Diseases. Prevent Diabetes Problems: Keep Your Heart and Blood Vessels Healthy. [PDF] NIH Publication No. 09–4283. 2009.
Lipid Management Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists’ (AACE) guidelines for management of dyslipidemia and prevention of atherosclerosis. [PDF] Endocr Pract. 2012 Mar/Apr;18(Suppl 1):1-78. Peripheral Arterial Disease (PAD)
BibliographyAntiplatelet Therapy Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. http://www.bmj.com/content/337/bmj.a1840.pdf%2Bhtml [PDF] Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al.; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010;33:1395-1402. http://care.diabetesjournals.org/content/33/6/1395.full.pdf+html [PDF] Blood Pressure Management Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive blood-pressure control in type 2 diabetes. N Eng J Med. 2010 Apr 29;362:1575-85. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al.; ACCORD Study Group. Effects of intensive lifestyle blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362:918-29. http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001286 [PDF] Friedman E. Optimizing care in diabetes: a quixotic challenge. Diabetes Care. 2012 Jun;35(6):1204-5. Holman RR, Paul SK, Bethel MA, Neil AW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Eng J Med. 2008;359(15):1565-76. Indian Health Service diabetes care and outcomes audit, unpublished data. Albuquerque (NM): Department of Health and Human Services (US), Indian Health Service, Office of Clinical and Preventive Services, Division of Diabetes Treatment and Prevention; 2011. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET). Circulation.2011 Oct 18; 124: 1727-36. http://circ.ahajournals.org/content/124/16/1727.full.pdf+html [PDF] National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): Department of Health and Human Services (US), National Institutes of Health, National Heart, Lung, and Blood Institute; 2004 Aug. 88 p. (NIH Publication No. 04-5230). Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, ONTARGET Investigators, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. http://circ.ahajournals.org/content/124/16/1727.full Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al.; the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med. 2001 Jan 4;344(1):3-10. United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. BMJ. 1998;317:703-13. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organisation (WHO) International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–1992. http://www.who.int/cardiovascular_diseases/guidelines/hypertension_guidelines.pdf [PDF] Zhang Y, Galloway JM, Welty TK, Wiebers DO, Whisnant JP, Devereaux RB, et al. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation. 2008;118:1577-84. Cardiovascular Care Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59. http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802743 [PDF] ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72. http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802987 [PDF] Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. AHA/ADA scientific statement: primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-26. http://circ.ahajournals.org/content/115/1/114.full.pdf+html [PDF] Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360:129-39. http://www.nejm.org/doi/pdf/10.1056/NEJMoa0808431 [PDF] Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, 2010. Circulation. 2010 Nov 12;122:e584-e636. http://circ.ahajournals.org/content/122/25/2748.full.pdf+html [PDF] Lee ET, Howard BV, Wang W, Welty TK, Galloway JM, Best LG, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation. 2006;113(25):2897-2905. http://circ.ahajournals.org/content/113/25/2897.full.pdf+html [PDF] Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009; 53:298-304. http://content.onlinejacc.org/article.aspx?articleid=1139360 Wilson PWF, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB. Prediction of incipient diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068-74. http://archinte.jamanetwork.com/article.aspx?articleid=486842 Lipid Management ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362:1563-74. http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001282 [PDF] Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr;31(4): 811-22. http://care.diabetesjournals.org/content/31/4/811.full.pdf+html [PDF] Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-16. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2802%2909327-3/abstract Indian Health Service diabetes care and outcomes audit, unpublished data. Albuquerque (NM): Department of Health and Human Services (US), Indian Health Service, Office of Clinical and Preventive Services, Division of Diabetes Treatment and Prevention; 2011. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28(8):1916-21. http://care.diabetesjournals.org/content/28/8/1916.full.pdf+html [PDF] Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 2003;26(1):16-23. http://care.diabetesjournals.org/content/26/1/16.full.pdf+html [PDF] National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III final report). Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2002 Sep. 280 p. (NIH Publication No. 02-5215). http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf [PDF] Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al.; Look AHEAD Research Group. Benefits of weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-6. http://care.diabetesjournals.org/content/34/7/1481.full.pdf+html [PDF] Peripheral Arterial Disease Lamar Welch VL, Casper M, Greenlund K, Zheng ZJ, Giles W, Rith-Najarian S. Prevalence of lower extremity arterial disease defined by the ankle-brachial index among American Indians: the Inter-Tribal Heart Project. Ethn Dis. 2002;12(1):S1-63-7. http://www.ncbi.nlm.nih.gov/pubmed/11915849 Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107(5):753-6. http://circ.ahajournals.org/content/107/5/753.full.pdf+html [PDF] Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109(6):733-9. http://circ.ahajournals.org/content/109/6/733 Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline); a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2020-45. Epub 2011 Sep 29. http://content.onlinejacc.org/cgi/content/full/j.jacc.2011.08.023 |
||||||||||||||||||||||||||||